Acne vulgaris is a chronic, multifactorial inflammatory disease of the pilosebaceous unit affecting nearly all adolescents and a substantial proportion of adults. It is driven by four central mechanisms: follicular hyperkeratinization, increased sebum production, Propionibacterium acnes–associated dysbiosis and inflammation (now commonly referred to as Cutibacterium acnes), and activation of innate/adaptive immune responses. The interaction of these processes leads to open and closed comedones, inflammatory papules and pustules, and in more severe cases nodules and cysts that can scar.
Pathogenesis begins with follicular hyperkeratinization. Abnormal desquamation and altered keratinocyte differentiation narrow the follicular canal, forming microcomedones. As the channel becomes obstructed, sebum accumulates and the follicle expands. Increased androgen signaling—either from endogenous production or heightened follicular sensitivity—raises sebum output, which supplies lipids that support bacterial growth and biofilm formation by Cutibacterium acnes. This organism produces pro-inflammatory mediators, including lipases that release free fatty acids, which irritate the follicular wall and amplify inflammation. In parallel, immune pathways recruit neutrophils and mononuclear cells, and cytokines such as IL-1β, TNF-α, and other inflammatory mediators promote papulopustular lesions.
Clinically, acne is classified by lesion morphology and distribution. Comedonal acne predominates when closed comedones and open comedones dominate. Papulopustular acne includes erythematous papules and pustules and often responds well to topical anti-inflammatory and anti-bacterial therapies. Nodulocystic acne, characterized by deep nodules and cysts, is associated with greater risk of permanent scarring and typically requires systemic treatment. Acne conglobata and fulminans are rare severe variants. Adult female acne often correlates with hormonal fluctuations; androgen excess states, pregnancy/postpartum changes, and certain endocrine disorders can contribute. Differential diagnoses include rosacea, perioral dermatitis, folliculitis, and medication-induced eruptions, such as corticosteroid or androgen-related acne.
A key determinant of outcomes is the prevention of scarring and mitigation of psychological burden. Acne can cause significant psychosocial impairment, including anxiety, depressive symptoms, body image disturbance, and social withdrawal. Early, guideline-based treatment improves both cutaneous and mental health trajectories by reducing lesion count and inflammation before tissue remodeling occurs.
Evidence-based management proceeds from severity, lesion type, and risk of scarring. First-line topical therapy for mild to moderate acne commonly includes retinoids (e.g., adapalene, tretinoin, or tazarotene) that normalize follicular keratinization and possess anti-inflammatory activity. Topical benzoyl peroxide reduces Cutibacterium acnes via oxidative mechanisms and helps prevent antibiotic resistance. Topical antibiotics (commonly clindamycin) are used sparingly and typically combined with benzoyl peroxide. For inflammatory lesions, azelaic acid provides anti-inflammatory and antimicrobial effects and can be beneficial for post-inflammatory hyperpigmentation.
Moderate to severe acne or acne refractory to topical therapy may require systemic options. Oral antibiotics such as doxycycline or minocycline reduce inflammatory lesion burden; however, these should be time-limited and paired with benzoyl peroxide to limit resistance. Hormonal therapies can be effective for women with androgen-responsive acne, particularly combined oral contraceptives or anti-androgen agents such as spironolactone under clinician supervision. Severe nodulocystic acne with scarring risk warrants consideration of isotretinoin, which targets all four pathogenic mechanisms by decreasing sebum production, altering keratinization, and exerting anti-inflammatory effects. Isotretinoin requires careful monitoring for hepatic function, lipids, and teratogenic risk with strict pregnancy prevention programs where applicable.
Adjunctive strategies improve results and adherence. Gentle skin care, non-comedogenic moisturizers, and sunscreen support barrier function and reduce post-inflammatory hyperpigmentation. Evidence on diet suggests high glycemic load foods and some dairy components may exacerbate acne in susceptible individuals; a low glycemic index dietary pattern may be beneficial for some patients. Avoiding lesion manipulation reduces inflammation and scarring risk. While cosmetic procedures and physical modalities exist (e.g., light therapies), they are generally adjunctive; treatment selection should be individualized and grounded in severity.
Finally, treatment requires realistic expectations and time. Many topical and systemic therapies show partial improvement within 6–12 weeks, with more meaningful control by 3–4 months. Consistent use, correct application to acne-prone areas, and management of irritation with gradual titration are essential. If therapeutic goals are not met or scarring is emerging, timely escalation is recommended.
In summary, acne vulgaris is a mechanistically coherent disease of the pilosebaceous unit driven by comedogenesis, sebum excess, Cutibacterium acnes–associated inflammation, and immune activation. Accurate classification, early evidence-based therapy, prevention of scarring, and attention to psychological impact are central to optimal patient outcomes. Source: Oxecureofficial
Oxe’cure: ⚖️ ขอถามพยานว่า… น้องโฟร์ท หน้าใสไหม❓ ตอบแค่ “ใช่” หรือ “ไม่” #Oxecure #Oxecurethailand #OxecureAcneCareExpert #อ๊อกซีเคียว #OxecureXFourth. #breaking
— @Oxecureofficial May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
